2013 - Where it all started
In 2013, as he left academia and started his career in a private practice in cardiac electrophisiology, Dr. Jose Osorio. realized that the known
success and complications rates of most procedures were based on limited and outdated clinical trials, instead of real-world evidence reflecting the diversity of patients.
Dr. Osorio began collecting standardized data from all of his patients resulting in one of the largest real-world outcomes databases on radiofrequency ablation for atrial fibrillation ablation.
2019 - Creation of a complete market solution
In 2019, together with Gunther Schrappe, Dr. Osorio transformed his successful clinical experience into a complete market solution to leverage
and decentralize real-world data generation in the healthcare industry.
2020-2021 - Expansion
In 2020 and 2021 the company expanded its client base from one Real World Evidence (RWE) registry to two RWE registries with two leading electrophysiology device companies.
2022 - Expansion / Collaboration with FDA
In 2022, the company continued to expand the number of Real World Evidence registries, going beyond atrial fibrillation and into left atrial appendage closure.
Dr. Paul Varosy, one of the country’s leading outcomes researcher joined our team.
The company also started its first FDA labeling research study using RWE, implemented a retrospective research study to allow a startup to train its AI model and started its first clinical trial with sites in the U.S and Europe.
